Top

In the spotlight.

From media giants to exclusive industry publications, Humacyte stays in the news.



April 8, 2019

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

March 29, 2019

Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”

January 8, 2019

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

November 28, 2018

NC Companies Shine At SEBIO Forum

October 25, 2018

Humacyte Commences Phase II Vascular Trauma Trial

October 8, 2018

Humacyte Appoints Doug Blankenship as Chief Financial Officer

July 25, 2018

U.S. Kidney Patients Help Drive Care Innovation Patient insights Accelerate Research and Development

June 20, 2018

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

June 12, 2018

Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment

March 9, 2018

Humacyte Closes $75 Million Series C Financing

October 2, 2017

Humacyte Awarded $3.4 Million Contract Award from The U.S. Department of Defense

September 29, 2017

Humacyte Receives $14.1 Million Award from California Institute for Regenerative Medicine to Expand Clinical Applications of HUMACYL®

September 27, 2017

Humacyte Receives Award from the Medical Technology Enterprise Consortium

September 7, 2017

Humacyte Completes Patient Enrollment for Phase III Clinical Trial of Human Acellular Vessel

June 14, 2017

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

April 25, 2017

Humacyte Founder Laura Niklason, M.D., Ph.D. Recognized on Fortune Magazine’s List of Leaders Transforming Health and Medicine

March 20, 2017

Humacyte Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Expedited Review Designation for HUMACYL® in Vascular Access for Hemodialysis

December 29, 2016

Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial

August 8, 2016

California Institute for Regenerative Medicine Awards $9.9 Million Grant for the Development of HUMACYL®

May 13, 2016

Humacyte Commences Phase III Clinical Trial of Human Acellular Vessel

May 13, 2016

Humacyte’s Phase II Bioengineered Blood Vessel Study Results Published in The Lancet

April 25, 2016

Humacyte Chief Medical Officer Jeffrey H. Lawson M.D., Ph.D. Elected to Fellowship in the American Surgical Association

November 9, 2015

Humacyte’s Chief Medical Officer and Vascular Surgeon, Dr. Jeffrey Lawson, to Address Upcoming VEITHsymposium

November 2, 2015

Humacyte Founder Laura Niklason, M.D., Ph.D. to Present at the American Heart Association Scientific Sessions

October 20, 2015

Humacyte Raises $150 Million Series B Financing

October 20, 2015

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Medicine

October 5, 2015

Humacyte Appoints Dr. Jeffrey H. Lawson as Chief Medical Officer

September 8, 2015

Humacyte Founder Dr. Laura Niklason and Board Director Dr. Robert Langer to address the 4th TERMIS World Congress in Boston

September 2, 2015

Humacyte Appoints the Honorable Kathleen Sebelius and Dale A. Sander to Board of Directors

May 28, 2015

Vascular Surgeon Dr. Jeffrey H. Lawson to Present on Tissue Engineering of Vascular Access Grafts at 2015 VASA Practicum

March 2, 2015

Humacyte Receives 2015 North Carolina Excellence Award

January 26, 2015

Surgeon, Dr. Jeffrey H. Lawson, to Present on Bioengineering and the Potential to Create New Blood Vessels at the International Symposium for Endovascular Therapy

October 20, 2014

Humacyte Selected to Join U.S. Secretary of Commerce On Trade Mission to Asia

July 23, 2014

Humacyte Receives Fast Track Designation for HumaGraft™ for Vascular Access in Hemodialysis Program

November 20, 2013

Humacyte Presents Interim First-In-Human Data For Investigational Bioengineered Blood Vessel At The American Heart Association (AHA) Scientific Sessions 2013

November 19, 2013

Investigational Bioengineered Vessels Update Is Presented at the 40th Annual VEITHsymposium in New York

October 31, 2013

Humacyte Receives 2013 North Carolina Excellence Award

October 11, 2013

AlloSource and Humacyte Become Strategic Manufacturing Partners to Create Investigational Bioengineered Blood Vessels from Tissue Donor Cells

June 6, 2013

Surgeons at Duke University Hospital Implant Bioengineered Vein

April 26, 2013

Humacyte Announces Clinical Milestones in its Novel Bioengineered Investigational Biologic Blood Vessel Technology

April 25, 2013

“Off-the-shelf” Investigational Biologic Artificial Blood Vessels May Reduce Dialysis Complications

October 3, 2011

Humacyte in Popular Mechanics

February 2, 2011

Science Translational Medicine

June 18, 2019

Entrepreneurial Journey

May 27, 2019

First Penn Scholarship Recipient off to Yale

May 23, 2019

Oh, the Places Grads Go

May 22, 2019

Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient

May 10, 2019

Bioengineered blood vessels could replace vasculature damaged by renal failure, CVD

April 9, 2019

Artificial blood vessels that come to life could improve medical care. Here’s why

April 4, 2019

TBJ reveals 2019 Life Sciences Awards winners

March 29, 2019

Study finds Humacyte acellular vessels repopulated to create living vessels

March 29, 2019

Scientists Make Blood Vessels From Cadaver Tissues And Bring Them to Life in Patients

March 28, 2019

Lab-grown blood vessels provide hope for dialysis patients

March 28, 2019

Scientists Grew Artificial Blood Vessels from Cadaver Cells

March 28, 2019

Bioengineered Blood Vessels Improve Long-Term Dialysis Experience

March 28, 2019

Lab-Grown Blood Vessels Could Treat Multiple Condition

March 28, 2019

Long term study finds engineered blood vessels turned to living tissue

March 27, 2019

Lab-grown blood vessels given to people who need dialysis

March 27, 2019

Blood vessels built from a patient’s cells could help people on dialysis

March 27, 2019

Scientists Create Blood Vessels That Become Living Tissue

March 27, 2019

Lab-grown blood vessels could make dialysis easier

March 27, 2019

Test Tube Blood Vessels Coming Alive: Study

March 7, 2019

VC Funding Is Hard to Come by If You’re a Female Founder

March 1, 2019

Inside the List: Largest Triangle VC fundraises in 2018

February 8, 2019

Biotech/Pharma Companies in Raleigh-Durham-Chapel Hill

January 28, 2019

Funding For Female Founders Stalled at 2.2% of VC Dollars in 2018

October 26, 2018

Humacyte launches Phase II vascular trauma Humacyl vessel trial

October 19, 2018

2018 Innovation Awards: Individuals

September 13, 2018

Licensing and Ventures Has Record Year

August 24, 2018

2018 C-Suite Award Winners

August 20, 2018

Kidney disease is a killer. More precise classification can help tame it

August 18, 2018

Dr. Shannon Dahl named to the 2018 PharmaVoice 100 list

July 10, 2018

Healthcare startups raise $15B across 779 deals in first half of year

July 9, 2018

Theranos? Whatever. Healthcare Startups Have Raised $15 Billion So Far This Year

July 5, 2018

Fresenius Medical Care offers $585m in notes

June 22, 2018

Bioengineered Blood Vessel Aims to Revolutionize Dialysis Access

June 20, 2018

Humacyte gets $150M, Fresenius distribution deal ahead of phase III data for acellular vessel

June 19, 2018

In wake of $150M deal, Humacyte names new CEO

June 12, 2018

Fresenius Medical Care to market Humacyte’s bioengineered blood vessel

June 11, 2018

Regenerative Specialist Humacyte Gets $150 Million Jolt from Fresenius

June 11, 2018

FMC takes stake in Humacyte in bet on bioengineered blood vessel

June 11, 2018

Fresenius inks $150M deal to bring Humacyte’s blood vessel implant to its dialysis clinics

June 11, 2018

Fresenius Medical Care, Humacyte ink $150m strategic partnership deal

June 11, 2018

Durham’s Humacyte lands $150M from Fresenius Medical Care

May 22, 2018

A look back at the CNBC Disruptor 50: 6 years, 167 companies

May 18, 2018

Humacyte: Bioengineered Human Blood Vessel Enters Pivotal Trials

March 18, 2018

Meet Ted Lithgow, Ph.D. and Jeffrey H. Lawson, M.D., Ph.D.with Humacyte, Inc

March 12, 2018

With a fresh $75 million, Humacyte now has raised more than $330 million

March 9, 2018

Regenerative Medicine Company Humacyte Raises $75 Million Series C

February 19, 2018

RMAT vs. Breakthrough vs. Fast Track: Companies Seek Clarity on FDA Draft Guidance

February 9, 2018

Biotech/Pharma Companies

November 16, 2017

FDA Unveils New Regenerative Medicine Framework

October 2, 2017

Humacyte lands $17.5M more in funding as it plots RTP growth

September 29, 2017

Humacyte lands $14m to expand uses for human acellular vessel

September 28, 2017

Looking toward FDA approval, RTP’s Humacyte scores funding

August 29, 2017

NHLBI publishes online article on Humacyte’s Next-generation replacement blood vessels target kidney and heart disease

June 19, 2017

Humacyte Tabbed as ‘Technology Pioneer’ by World Economic Forum

May 30, 2017

Profiles in Diversity Journal Announces its 2017 Women Worth Watching Awards

May 22, 2017

New FDA Pathway to Accelerate Development of Cell Therapies

May 9, 2017

110 Women in Medtech to Know

March 26, 2017

US FDA First’s RMAT Designation: Humacyte Got A ‘Quick Response’

March 22, 2017

US FDA fast-track designation for Humacyte’s tissue-based hemodialysis product

March 20, 2017

Humacyte Receives First of FDA’s Regenerative Medicine Designations

March 20, 2017

FDA Grants Regenerative Medicine Designation to Humacyte Vascular Tissue Therapy

March 8, 2017

9 women medtech leaders you need to know

December 30, 2016

Humacyte launches Phase II trial for artificial bypass graft in PAD

December 29, 2016

Humacyte launches Phase 2 trial of artificial blood vessel

December 15, 2016

65 women leaders of medtech companies

December 1, 2016

Bioengineered Vessel Evaluated in Research Study

September 18, 2016

Innovator’s Corner: Jeffrey Lawson, M.D., Ph.D., Chief Medical Officer, Humacyte

September 12, 2016

Overlook Medical Center First-in-State to Implant Human-Tissue Vessel as Part of Hemodialysis Access Clinical Trial

August 26, 2016

137 healthcare entrepreneurs to know

August 9, 2016

RTP’s Humacyte gets $10M from California stem cell group

August 8, 2016

California Agency Awards Humacyte $9.9M for Blood Vessel Technology

July 6, 2016

Bioengineered Blood Vessels Offer Advantages

June 26, 2016

Six New Medical Technologies Worth Watching

June 8, 2016

Inside the sci-fi world of growing human tissue and organs in the lab

June 6, 2016

Humacyte, a bioengineered blood vessel

May 24, 2016

10 Women Who Would Be a Great Addition to Any Company’s Board

May 18, 2016

RTP’s Humacyte makes big steps with Lancet publication and Phase 3 Trial

May 13, 2016

Humacyte launches pivotal trial for lab-grown blood vessel

May 13, 2016

Langer startup reports data, starts pivotal trial for bioengineered blood vessel for dialysis patients

April 30, 2016

What Does It Take to Outperform the S&P 500? We Asked a Board Member Who Does It

April 7, 2016

3 emerging innovations for blood vessel repair

Awards &
Acknowledgements

Diversity Journal Women Worth Watching

Humacyte’s Sabrina Osborne, Vice President of Human Resources, was named a 2019 winner for Diversity Journal’s women Worth Watching list.

Triangle Business Journal Life Sciences Awards

Humacyte recognized for best late-stage product development company’ category.

Triangle Business Journal

List of Largest Biotech/Pharma Companies in the Triangle

Triangle Business Journal 2018 Innovation Awards

Humacyte President and Chief Executive Officer was selected to Triangle Business Journal’s 2018 Innovation Awards List.

Humacyte was named as a finalist in the Strategic Investment Category to the SEBIO 2018 Awards List

Humacyte was recognized for securing a $150M strategic investment from Fresenius Medical, the world’s largest dialysis company, to commercialize HUMACYL for dialysis applications.

Triangle Business Journal 2018 C-Suite Awards List

Humacyte Chief Regulatory Office Bill Tente was selected to Triangle Business Journal’s 2018 C-Suite List.

Diversity Journal Women’s Worth Watching

Gretchen Smith, Humacyte’s Executive Director, Manufacturing was named a 2018 winner for Diversity Journal’s Women Worth Watching list.

Humacyte Founder
Shannon Dahl’s, Ph.D. Named
to the 2018 PharmaVoice100
List Awards Finalist

Dr. Dahl was recognized by PharmaVoice for
breaking bioengineering ground,
with regenerative medicine.

Humacyte’s Theodore Lithgow, Chief Operations Officer, was recognized in the 2017 Best in Biz awards under the Executive of the Year

Humacyte’s Theodore Lithgow, Chief Operations Officer, was recognized in the 2017 Best in Biz awards under the Executive of the Year

Medical Design & Outsourcing: Humacyte’s Carrie Cox named to 9 Women Medtech Leaders You Need to Know list

Medical Design & Outsourcing: Humacyte’s Carrie Cox named to 9 Women Medtech Leaders You Need to Know list

Humacyte Founder
Laura Niklason, M.D., Ph.D. Named
to the 2017 PharmaVoice100
List Awards Finalist

Dr. Niklason was recognized by PharmaVoice for her
contributions to the advancement of regenerative medicine,
in creating investigational human acellular vessels.

Humacyte Founder
Laura Niklason, M.D., Ph.D. Inducted
into the Women in Technology (WITI) Hall of Fame

Dr. Niklason was inducted into the Women in Technology
Fall of Fame for her groundbreaking research in regenerative
strategies for cardiovascular and lung tissues.

Humacyte’s Heather Prichard, Ph.D.,
named as a 2017 award winner for
Diversity Journal’s Women Worth
Watching in STEM

Senior Vice President, Product Development Dr. Heather
Prichard was named as a 2017 award winner for Diversity
Journal’s Women Worth Watching in STEM in recognition of
her work to develop technologies for improving medical
treatment for a variety of diseases.

Humacyte® Selected as 2017
Technology Pioneer by
World Economic Forum

Humacyte was selected as a 2017 Technology Pioneer by
the World Economic Forum for the potential to significantly
impact business and society through new technologies
in regenerative medicine.

Humacyte’s Juliana Blum and
Jenny Jackson Named to Profiles
in Diversity Journal’s 2017 Women Worth Watching List

Dr. Juliana Blum, Co-Founder and Vice-President, Business
Operations & Tissue Services and Jenny Jackson, Associate
Director of Reimbursement for Humacyte, were recognized to
Diversity Journal’s Women Worth Watching in 2017 award for
their personal and professional contributions to advancing
gender diversity.

Humacyte Founder
Dr. Laura Niklason and Humacyte
CEO Carrie Cox Named to
Becker’s Hospital Review List
of 110 Women in Medtech to Know

Humacyte Founder, Dr. Niklason and Humacyte CEO,
Carrie Cox were both recognized to Becker’s Hospital
Review, “110 Women in Medtech to Know”

Humacyte Founder
Laura Niklason, M.D., Ph.D.
Recognized on Fortune
Magazine’s List of Leaders
Transforming Health and Medicine

Dr. Niklason was recognized to Fortune Magazine’s prestigious
List of Leaders Transforming Health and Medicine, for her
contributions to the advancement of regenerative medicine,
in creating investigational human acellular vessels.

Humacyte Founder Dr.
Laura Niklason, M.D., Ph.D.
awarded with a 2016
LAS Alumni Achievement Award

Dr. Laura Niklason received a LAS Alumni Achievement
Award from the University of Illinois College of Liberal
Arts & Sciences for groundbreaking work in tissue
engineering in 2016.

Humacyte named 2016 Fierce
Innovation Awards finalist

Humacyte was named to Fierce Innovation’s Awards Life
Sciences Edition in 2016 for creating HUMACYL

Humacyte named to FierceBiotech’s
Top 15 Private Companies in the
Medical Devices Space for 2016

Humacyte was named to FierceBiotech’s Top 15 Private
Companies in Medical Devices for the potential to significantly
impact business and society through new technologies
in regenerative medicine.

WSJ Includes Humacyl
as one of “Six New Medical
Technologies Worth Watching”

Humacyte was highlighted as a potential breakthrough
for patients undergoing hemodialysis.

Humacyte makes CNBC
Disruptor 50 List

Humacyte was named to CNBC’s prestigious Disrupt 50
List for the progress HUMACYL has made since
Humacyte’s founding.

Humacyte Chief Medical Officer
Jeffrey H. Lawson M.D., Ph.D.
Elected to Fellowship in
the American Surgical Association

Humacyte’s Chief Medical Officer, Dr. Jeffery H. Lawson
was elected as a Fellow to the prominent American Surgical
Association for his experience and leadership as a
medical professional.

Humacyte Founder
Laura Niklason, M.D., Ph.D.
Elected to National Academy of Medicine

Laura Niklason, M.D., Ph.D., a world leader in tissue
engineering and cellular therapies and Founder of Humacyte,
has been elected to the prestigious National Academy of
Medicine (NAM). NAM is an independent organization of
eminent professionals from diverse fields including health
and medicine; the natural, social, and behavioral sciences,
and beyond.

North Carolina
Excellence Award

Humacyte, an innovator in biotechnology and regenerative
medicine, announced today that the Company has been awarded
the 2015 North Carolina Excellence Award by the US Commerce
& Trade Research Institute (USCTRI), a leading research
authority that evaluates and recognizes businesses and
organizations that have made a significant contribution
in enterprise and entrepreneurial growth.

Excellence in
Commerce Award

The Small Business Institute for Excellence in Commerce
(SBIEC) recognizes Humacyte with the 2013 North Carolina
Excellence Award for continued advancement of business
leadership and high regard for upholding business ethics
and company values among its peers.

Top 10 Women
in Biotech

Fierce Biotech names Carrie Cox as one of the
“Top 10 Women in Biotech”

Fast Company 
Top 50 World’s Most
Innovative Companies

Fast Company names Humacyte as one of the “Top 50
World’s Most Innovative Companies”

Popular Mechanics 
Breakthrough Innovation of 2011

Popular Mechanics recognizes Humacyte investigational
bioengineered blood vessel technology as a “Breakthrough
Innovation of 2011.” This technology is under clinical
study by Humacyte, and Humacyte plans to seek FDA
approval of the technology.

Frost & Sullivan
New Product Innovation

Humacyte receives Frost & Sullivan Award for New
Product Innovation

Coming to a city near you.

EVENT
DATE
LOCATION
EVENT TYPE
American College of Surgeons (ACS) – Clinical Congress 2018
October 21-25, 2018
Boston, MA
Attendee
Sixth Annual Kidney Health Initiative (KHI) Stakeholders Meeting
May 14-15, 2018
Silver Springs, MD
Attendee
Charing Cross Symposium 2018
April 24-27, 2018
London, UK
Attendee
2018 Renal Physicians Association (RPA)
March 15 – 18, 2018
Orlando, FL
Presentation
2017 CNBC Net/Net Summit
October 25, 2017
New York, NY
Business & Networking
Women in Technology International 23rd Annual Women in Technology Summit
June 11-13, 2017
San Jose, California
Recognition & Panel Discussion
ASDIN (American Society of Diagnostic and Interventional Nephrology)
February 10-12, 2017
New Orleans, Louisiana
Presentation
American Heart Association Scientific Sessions
November 7-11, 2015
Orlando, FL
Recognition & Panel Discussion
TERMIS World Congress
September 8-11, 2015
Boston, Massachusetts
Recognition & Panel Discussion
Humacyte VASA Practicum Presentation
May 10-11, 2015
Houston, Texas
Presentation
42nd Annual Symposium on Vascular and Endovascular Issues
February 7, 2015
New York
Recognition & Panel Discussion
The 27th International Symposium on ISET
January 22-25, 2015
Hollywood, FL
Recognition & Panel Discussion
The Controversies in Dialysis Access Meeting
November 8, 2013
San Francisco, California
Presentation
Vascular Access Society Meeting
October 30, 2013
San Diego, California
Presentation
American Heart Association’s Emerging Science Series
June 19, 2013
Dallas, Texas
Presentation
Show past events